Takeda gout drug Uloric loses first-line approval after FDA confirms death risks

FDA has slapped a boxed warning on Takeda's gout drug Uloric due to an increased risk of death. (FDA)

Takeda's gout drug Uloric just got pushed out of the first-line treatment club, thanks to a red flag on safety.

After sifting postmarketing data, the FDA decided Uloric does carry an increased risk of death compared to the older gout drug allopurinol. The agency has slapped a boxed warning on Uloric's label and is limiting Uloric’s use to patients “who have failed or do not tolerate allopurinol.”

That means the Takeda medication will be forced into a smaller population of some 8.3 million adult gout patients in the U.S. And that could cut seriously into the growth Uloric's been posting for the Japanese drugmaker.

Cambrex Webinar

Understanding the Importance of Crystallization Processes to Avoid Unnecessary Cost, Risk and Development Delays

Wednesday, May 27, 2020 | 10am ET / 7am PT

A well-developed crystallization process can produce suitable particles that can facilitate consistent filtration, drying and formulation of the API and allow confident and reliable manufacturing of the final drug product, while avoiding unnecessary cost, risk and development delays.

“We believe the label updates are appropriate to ensure physicians and patients have comprehensive and accurate information to make informed treatment decisions,” a Takeda spokeswoman told FiercePharma in an emailed statement.

Uloric was approved by the FDA in 2009 after two failed attempts in 2005 and 2006. The agency turned Uloric back then because of cardiovascular problems that cropped up in clinical trials. A follow-up trial Takeda ran for its third run at approval didn’t raise the same safety flag, so the FDA gave Uloric a green light, but included the CV safety data in the “Warning and Precaution” section of its label.

The FDA also required Takeda to run a large postmarketing safety study—and the data once again showed reason for worry.

RELATED: Takeda hits FDA snag on Ninlaro, but its growth still helps drive revenue hike

“The imbalance in cardiovascular deaths between the two treatments was unexpected and warrants further analyses,” William White of the University of Connecticut School of Medicine, the lead investigator of the postmarket study, said in a statement last March.

In the 6,190-patient trial, Uloric’s rates of CV-related death and death from all causes were notably higher than those for allopurinol. The findings prompted a petition from nonprofit consumer advocacy group Public Citizen calling on the agency to pull Uloric’s approval.

Uloric is one of the growing drugs in Takeda’s portfolio. In the nine months ended in December, it raked in 40.5 billion Japanese yen ($366 million), up 15.7% year over year, with almost all sales coming from the U.S. The boxed warning and restriction to second-line use could put the drug’s growth in jeopardy.

Editor's Note: The story has been updated with a statement from Takeda.

Suggested Articles

BMS' Opdivo and Yervoy only just won their first approval in previously untreated metastatic NSCLC, but the pair is already making it two.

Wrapping up the legal battle at $10 billion would be a win for Bayer, as it has lost $30 billion in market value since the Monsanto buyout.

Takeda’s Alunbrig has arrived in previously untreated, ALK-positive NSCLC. But there’s plenty of competition waiting to greet it at the door.